BACKGROUND
Updated formulations for the Moderna, Pfizer-BionTech, and Novavax have been released. All previously approved COVID-19 vaccine formulations became deauthorized upon FDA approval of the 2023-2024 vaccine formulations. Administration of deauthorized formulations should be reported to the VAERS system.

This technical bulletin summarizes the updated and simplified use of Novavax, Pfizer-BioNTech and Moderna's COVID-19 vaccines (2023-2024 formulation), including eligibility, schedule and recommendations for individuals 65 years and older.

Timeline
On Sept. 11, 2023, the U.S. Food and Drug Administration (FDA) issued approval and Emergency Use Authorizations (EUAs) to both Moderna and Pfizer-BioNTech for their updated COVID-19 monovalent mRNA vaccines that correspond with the Omicron XBB.1.5 variant. This is to provide the public with better coverage and protection from serious illness and complications from the currently circulating strains of COVID-19.

As of Sept. 11, 2023, all bivalent Moderna and Pfizer-BioNTech mRNA COVID-19 vaccines are no longer authorized for use in the United States, regardless of age. Administration of any bivalent Moderna or Pfizer-BioNTech mRNA COVID-19 vaccines are now considered vaccine administration errors and must be reported to the Vaccine Adverse Event Reporting System (VAERS).

On Sept. 12, 2023, the Centers for Disease Control and Prevention (CDC) issued a recommendation that all individuals aged 6 months and older receive an updated COVID-19 vaccine to protect against serious outcomes of COVID-19 illness, such as hospitalization or death, as well as reducing the chance of being affected by Long COVID.

On Oct. 3, 2023, the FDA amended the EUA of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA COVID-19 vaccine) are eligible to receive one dose, and unvaccinated individuals receive two doses.
On Feb. 28, 2024, the CDC's Advisory Council on Immunization Practices (ACIP) recommended that adults ages 65 years and older should receive an additional updated 2023-2024 COVID-19 vaccine dose. This recommendation acknowledges the increased risk of severe disease from COVID-19 in older adults.

**Links to Updated Guidance**

Visit the links below for CDC's most current COVID-19 vaccine eligibility and schedule for people who are not moderately or severely immunocompromised, by age.

- **Ages 6 months – 4 years**
- **Ages 5-11 years**
- **Ages 12 years and older**

Visit the links below for CDC's most current COVID-19 vaccine eligibility and schedule for people who are moderately or severely immunocompromised, by age.

- **Ages 6 months – 4 years**
- **Ages 5-11 Years**
- **Ages 12 years and older**

For more information and/or additional resources, the CDC has published updated interim clinical considerations, including updated guidance on reporting vaccine adverse events and errors to the Vaccine Adverse Event Reporting System (VAERS).

**Vaccine Information Fact Sheets and Prescribing Information**

Pfizer-BioNTech's Vaccine Information Fact Sheets have been updated for Recipients and/or Caregivers and Healthcare Providers, which are available for reference.

*Comirnaty Prescribing Information* sheets are available for reference.

Moderna's Vaccine Information Fact Sheets have also been updated for Recipients and/or Caregivers and Healthcare Providers which are available for reference.

*Spikevax Prescribing Information* sheets are available for reference.

Novavax's Vaccine Information Fact Sheets have been updated for Recipients and/or Caregivers and Healthcare Providers, which are available for reference.

**Questions**

For updated guidance, review the Division of Public and Behavioral Health Technical Bulletin web page regularly. Email nviz@health.nv.gov for other questions regarding COVID vaccination.

Cody Phinney, MPH
Administrator
Division of Public and Behavioral Health

Ihsan Azzam, Ph.D., M.D.
Chief Medical Officer
Division of Public and Behavioral Health